{"downloaded": true, "htmlmade": false, "full": {"id": "30396908", "source": "MED", "pmid": "30396908", "pmcid": "PMC7814996", "fullTextIdList": {"fullTextId": "PMC7814996"}, "doi": "10.1158/2326-6066.cir-18-0307", "title": "Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.", "authorString": "Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S.", "authorList": {"author": [{"fullName": "Baumeister SH", "firstName": "Susanne H", "lastName": "Baumeister", "initials": "SH", "authorId": {"@type": "ORCID", "#text": "0000-0003-3846-5156"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}, {"affiliation": "Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}, {"affiliation": "Division of Pediatric Hematology-Oncology Boston Children's Hospital, Boston, Massachusetts."}, {"affiliation": "Harvard Medical School, Boston, Massachusetts."}]}}, {"fullName": "Murad J", "firstName": "Joana", "lastName": "Murad", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Celdara Medical, LLC, Lebanon, New Hampshire."}}}, {"fullName": "Werner L", "firstName": "Lillian", "lastName": "Werner", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Daley H", "firstName": "Heather", "lastName": "Daley", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Trebeden-Negre H", "firstName": "Helene", "lastName": "Trebeden-Negre", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Gicobi JK", "firstName": "Joanina K", "lastName": "Gicobi", "initials": "JK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Schmucker A", "firstName": "Adam", "lastName": "Schmucker", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Celdara Medical, LLC, Lebanon, New Hampshire."}}}, {"fullName": "Reder J", "firstName": "Jake", "lastName": "Reder", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0002-7975-9874"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Celdara Medical, LLC, Lebanon, New Hampshire."}}}, {"fullName": "Sentman CL", "firstName": "Charles L", "lastName": "Sentman", "initials": "CL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire."}}}, {"fullName": "Gilham DE", "firstName": "David E", "lastName": "Gilham", "initials": "DE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Celyad, SA, Mont-Saint-Guibert, Belgium."}}}, {"fullName": "Lehmann FF", "firstName": "Fr\u00e9d\u00e9ric F", "lastName": "Lehmann", "initials": "FF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Celyad, SA, Mont-Saint-Guibert, Belgium."}}}, {"fullName": "Galinsky I", "firstName": "Ilene", "lastName": "Galinsky", "initials": "I", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "DiPietro H", "firstName": "Heidi", "lastName": "DiPietro", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Cummings K", "firstName": "Kristen", "lastName": "Cummings", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Munshi NC", "firstName": "Nikhil C", "lastName": "Munshi", "initials": "NC", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}, {"affiliation": "Harvard Medical School, Boston, Massachusetts."}]}}, {"fullName": "Stone RM", "firstName": "Richard M", "lastName": "Stone", "initials": "RM", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}, {"affiliation": "Harvard Medical School, Boston, Massachusetts."}]}}, {"fullName": "Neuberg DS", "firstName": "Donna S", "lastName": "Neuberg", "initials": "DS", "authorId": {"@type": "ORCID", "#text": "0000-0003-2566-3145"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}}}, {"fullName": "Soiffer R", "firstName": "Robert", "lastName": "Soiffer", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}, {"affiliation": "Harvard Medical School, Boston, Massachusetts."}]}}, {"fullName": "Dranoff G", "firstName": "Glenn", "lastName": "Dranoff", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Novartis BioMedical Institutes, Cambridge, Massachusetts."}}}, {"fullName": "Ritz J", "firstName": "Jerome", "lastName": "Ritz", "initials": "J", "authorId": {"@type": "ORCID", "#text": "0000-0001-5526-4669"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts."}, {"affiliation": "Harvard Medical School, Boston, Massachusetts."}]}}, {"fullName": "Nikiforow S", "firstName": "Sarah", "lastName": "Nikiforow", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts. sarah_nikiforow@dfci.harvard.edu."}, {"affiliation": "Harvard Medical School, Boston, Massachusetts."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-5526-4669"}, {"@type": "ORCID", "#text": "0000-0002-7975-9874"}, {"@type": "ORCID", "#text": "0000-0003-2566-3145"}, {"@type": "ORCID", "#text": "0000-0003-3846-5156"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "1", "volume": "7", "journalIssueId": "2765576", "dateOfPublication": "2019 Jan", "monthOfPublication": "1", "yearOfPublication": "2019", "printPublicationDate": "2019-01-01", "journal": {"title": "Cancer immunology research", "ISOAbbreviation": "Cancer Immunol Res", "medlineAbbreviation": "Cancer Immunol Res", "NLMid": "101614637", "ISSN": "2326-6066", "ESSN": "2326-6074"}}, "pubYear": "2019", "pageInfo": "100-112", "abstractText": "NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or poorly expressed on healthy tissues. We conducted a phase I dose-escalation study to evaluate the safety and feasibility of a single infusion of NKG2D-chimeric antigen receptor (CAR) T cells, without lymphodepleting conditioning in subjects with acute myeloid leukemia/myelodysplastic syndrome or relapsed/refractory multiple myeloma. Autologous T cells were transfected with a \u03b3-retroviral vector encoding a CAR fusing human NKG2D with the CD3\u03b6 signaling domain. Four dose levels (1 \u00d7 10<sup>6</sup>-3 \u00d7 10<sup>7</sup> total viable T cells) were evaluated. Twelve subjects were infused [7 acute myeloid leukemia (AML) and 5 multiple myeloma]. NKG2D-CAR products demonstrated a median 75% vector-driven NKG2D expression on CD3<sup>+</sup> T cells. No dose-limiting toxicities, cytokine release syndrome, or CAR T cell-related neurotoxicity was observed. No significant autoimmune reactions were noted, and none of the \u2265 grade 3 adverse events were attributable to NKG2D-CAR T cells. At the single injection of low cell doses used in this trial, no objective tumor responses were observed. However, hematologic parameters transiently improved in one subject with AML at the highest dose, and cases of disease stability without further therapy or on subsequent treatments were noted. At 24 hours, the cytokine RANTES increased a median of 1.9-fold among all subjects and 5.8-fold among six AML patients. Consistent with preclinical studies, NKG2D-CAR T cell-expansion and persistence were limited. Manufactured NKG2D-CAR T cells exhibited functional activity against autologous tumor cells <i>in vitro</i>, but modifications to enhance CAR T-cell expansion and target density may be needed to boost clinical activity.", "affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "P01 CA066996", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "R44 HL099217", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "T-Lymphocytes", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Myelodysplastic Syndromes", "meshQualifierList": {"meshQualifier": {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytokines", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Ligands"}, {"majorTopic_YN": "Y", "descriptorName": "Immunotherapy, Adoptive"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "NK Cell Lectin-Like Receptor Subfamily K", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Receptors, Chimeric Antigen", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}]}, "chemicalList": {"chemical": [{"name": "Ligands", "registryNumber": "0"}, {"name": "Cytokines", "registryNumber": "0"}, {"name": "NK Cell Lectin-Like Receptor Subfamily K", "registryNumber": "0"}, {"name": "KLRK1 protein, human", "registryNumber": "0"}, {"name": "Receptors, Chimeric Antigen", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/2326-6066.CIR-18-0307"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7814996"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7814996?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/2326-6066.cir-18-0307"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "53", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS1511717", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2020-03-04", "dateOfCreation": "2018-11-07", "firstIndexDate": "2018-11-06", "fullTextReceivedDate": "2021-01-21", "dateOfRevision": "2021-02-02", "electronicPublicationDate": "2018-11-05", "firstPublicationDate": "2018-11-05"}, "abstract": "NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or poorly expressed on healthy tissues. We conducted a phase I dose-escalation study to evaluate the safety and feasibility of a single infusion of NKG2D-chimeric antigen receptor (CAR) T cells, without lymphodepleting conditioning in subjects with acute myeloid leukemia/myelodysplastic syndrome or relapsed/refractory multiple myeloma. Autologous T cells were transfected with a \u03b3-retroviral vector encoding a CAR fusing human NKG2D with the CD3\u03b6 signaling domain. Four dose levels (1 \u00d7 10<sup>6</sup>-3 \u00d7 10<sup>7</sup> total viable T cells) were evaluated. Twelve subjects were infused [7 acute myeloid leukemia (AML) and 5 multiple myeloma]. NKG2D-CAR products demonstrated a median 75% vector-driven NKG2D expression on CD3<sup>+</sup> T cells. No dose-limiting toxicities, cytokine release syndrome, or CAR T cell-related neurotoxicity was observed. No significant autoimmune reactions were noted, and none of the \u2265 grade 3 adverse events were attributable to NKG2D-CAR T cells. At the single injection of low cell doses used in this trial, no objective tumor responses were observed. However, hematologic parameters transiently improved in one subject with AML at the highest dose, and cases of disease stability without further therapy or on subsequent treatments were noted. At 24 hours, the cytokine RANTES increased a median of 1.9-fold among all subjects and 5.8-fold among six AML patients. Consistent with preclinical studies, NKG2D-CAR T cell-expansion and persistence were limited. Manufactured NKG2D-CAR T cells exhibited functional activity against autologous tumor cells <i>in vitro</i>, but modifications to enhance CAR T-cell expansion and target density may be needed to boost clinical activity.", "journaltitle": "Cancer immunology research", "authorinfo": ["Baumeister SH", "Murad J", "Werner L", "Daley H", "Trebeden-Negre H", "Gicobi JK", "Schmucker A", "Reder J", "Sentman CL", "Gilham DE", "Lehmann FF", "Galinsky I", "DiPietro H", "Cummings K", "Munshi NC", "Stone RM", "Neuberg DS", "Soiffer R", "Dranoff G", "Ritz J", "Nikiforow S"], "title": "Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma."}